Skip to main content
Premium Trial:

Request an Annual Quote

Rosetta Genomics Stock Surges on Lung Cancer Dx Findings

NEW YORK (GenomeWeb News) – Rosetta Genomics' stock soared 72 percent in mid-afternoon trading on Nasdaq after announcing a successful clinical study on one of its lung cancer diagnostic tests.

The Rehovot, Israel-based company's share price rose $1.33 to $3.18 from yesterday's close of $1.85.

A joint study by the company and Johns Hopkins University showed that the firm's miRview squamous non-small cell lung cancer diagnostic accurately classified NSCLC samples from resection and from fine-needle aspirate cell blocks, Rosetta said.

The miRview test, offered in the US by Prometheus Laboratories under the brand name ProOnc, is a microRNA-based molecular assay that classifies NSCLCs using the expression level of a single microRNA biomarker.

Details of the research are set to be published in the January 15 issue of the American Association for Cancer Research’s journal Clinical Cancer Research.

Rosetta Genomics' CEO, Ken Berlin, said in a statement that the study validated the miRview test's "sensitivity, specificity, reproducibility, and overall reliability in helping physicians accurately make this critical lung cancer classification."

The Scan

UK Pilot Study Suggests Digital Pathway May Expand BRCA Testing in Breast Cancer

A randomized pilot study in the Journal of Medical Genetics points to similar outcomes for breast cancer patients receiving germline BRCA testing through fully digital or partially digital testing pathways.

Survey Sees Genetic Literacy on the Rise, Though Further Education Needed

Survey participants appear to have higher genetic familiarity, knowledge, and skills compared to 2013, though 'room for improvement' remains, an AJHG paper finds.

Study Reveals Molecular, Clinical Features in Colorectal Cancer Cases Involving Multiple Primary Tumors

Researchers compare mismatch repair, microsatellite instability, and tumor mutation burden patterns in synchronous multiple- or single primary colorectal cancers.

FarGen Phase One Sequences Exomes of Nearly 500 From Faroe Islands

The analysis in the European Journal of Human Genetics finds few rare variants and limited geographic structure among Faroese individuals.